Building a distinctive brand.
Funding disciplined growth.

We believe the peptide category offers room for recognisable specialist brands that combine clear information, consistent presentation and dependable service.

Our commercial interest is in the wider peptide category, including interest among adults engaged with fitness, sport and health. However, consumer interest does not itself establish a permitted route to supply or promote a particular product.

An important uncertainty is the boundary between research-product supply and consumer-facing demand. We cannot assume that products presented for research can be promoted or supplied for human use. Product selection, customer eligibility, claims and acquisition channels must therefore be assessed against the actual intended business model before launch.

The investment would fund this assessment alongside the commercial foundations. The launch scope will be defined by what can be legitimately supplied, marketed and supported by payment providers, with products or channels excluded where a suitable route cannot be established.

The wider peptide field includes distinct markets with different product, supply and advertising requirements. Peptomera Pro’s addressable opportunity will be defined around the products, customers and activities it can legitimately serve.

Our aim is to establish that opportunity, validate the economics and build a repeatable growth model.

Across an initial trading period from March to 27 September 2026, Peptomera recorded £12,456.85 in net product sales across 100 reported orders. Including shipping, recorded sales totalled £12,711.54. This provides an early commercial foundation from which to assess customer demand and develop the next phase.

Average order value before sales reversals and excluding shipping was approximately £131.83. Peptomera trading records show 22 returning customers, providing initial evidence of repeat purchasing. Peptomera Pro remains pre-launch.

Our initial competitor review found suppliers already promoting testing, product documentation, branded presentation and fast fulfilment.

These features form part of the competitive standard. Peptomera Pro intends to compete through the combined execution of assortment, presentation, information, service and operational consistency.

The test is whether customers choose the brand, return to it and can be acquired at a cost supported by order contribution.

Over time, we aim to strengthen the business through customer insight, reliable supplier relationships and a reputation supported by delivery.

The products and prices below are a selected sample for initial commercial modelling, rather than the full proposed range. Management reports access to a substantially broader supplier catalogue and supply options beyond these examples.

The launch assortment will be selected from that wider pool according to demand, product suitability, supplier assessment, availability and full landed economics. Expansion will follow evidence from the initial range.

The financial model will incorporate packaging, import costs, appropriate testing, payment processing, fulfilment, refunds, customer service and acquisition.

The historical Peptomera order value will not be assumed for Pro without supporting evidence.

We are seeking investment to launch Peptomera Pro and prove a repeatable, scalable commercial model.

Funding would establish the operating foundations, support initial inventory and testing, and place substantial emphasis on specialist marketing and customer acquisition. Expenditure would increase as measured performance supports expansion.

We are open to a staged investment structure, with an initial tranche funding launch and validation, and further capital released against agreed milestones.

The final allocation and runway will be refined through partner quotations and a detailed monthly cash-flow model.

A dedicated privately held entity is proposed for Peptomera Pro, with offshore incorporation under consideration.

The jurisdiction and any operating subsidiaries will be selected with professional advisers, taking account of investor requirements, management location, banking, payments and intended trading activities.

The entity would hold or obtain documented rights to the Pro brand, domain, website, relevant intellectual property and supplier contracts.

Any transfer of assets or permitted customer information from existing Peptomera would be separately documented.

Ownership and beneficial-owner information will be disclosed to investors, banks, service providers and authorities as required.

The proposed commercial route must reflect the actual products and intended customers. Research-only terminology is not the basis of the investment proposition.